Hugel Aesthetics Scales U.S. Operations for Letybo Neurotoxin

Since receiving FDA approval in February 2024, Letybo has been integrated into the service offerings of over 9,000 aesthetic practices. While the company maintains its strategic partnership with BENEV Company Inc., the new internal sales organization will focus on high-impact accounts, effectively splitting the distribution landscape. This expansion coincides with the rollout of K-TOX, a marketing campaign highlighting the product’s decade-long status as a market leader in South Korea.

Beyond commercial scaling, Hugel is intensifying its investment in clinical research and medical congress support. Carrie Strom, President and Global CEO, emphasized that the initiative aims to provide practitioners with deeper scientific education and resources. Dr. Michael H. Gold, a U.S. Letybo investigator, noted that access to these field teams and emerging clinical data is critical for clinicians navigating the competitive neurotoxin market. The company plans to continue this dual-pronged approach throughout 2026, balancing partner-led distribution with its own specialized medical affairs support.